These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 15735612)

  • 1. Inhibition of human intestinal wall metabolism by macrolide antibiotics: effect of clarithromycin on cytochrome P450 3A4/5 activity and expression.
    Pinto AG; Wang YH; Chalasani N; Skaar T; Kolwankar D; Gorski JC; Liangpunsakul S; Hamman MA; Arefayene M; Hall SD
    Clin Pharmacol Ther; 2005 Mar; 77(3):178-88. PubMed ID: 15735612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin.
    Gorski JC; Jones DR; Haehner-Daniels BD; Hamman MA; O'Mara EM; Hall SD
    Clin Pharmacol Ther; 1998 Aug; 64(2):133-43. PubMed ID: 9728893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diltiazem inhibits human intestinal cytochrome P450 3A (CYP3A) activity in vivo without altering the expression of intestinal mRNA or protein.
    Pinto AG; Horlander J; Chalasani N; Hamman M; Asghar A; Kolwankar D; Hall SD
    Br J Clin Pharmacol; 2005 Apr; 59(4):440-6. PubMed ID: 15801939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5.
    Mouly SJ; Matheny C; Paine MF; Smith G; Lamba J; Lamba V; Pusek SN; Schuetz EG; Stewart PW; Watkins PB
    Clin Pharmacol Ther; 2005 Dec; 78(6):605-18. PubMed ID: 16338276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity.
    Gorski JC; Vannaprasaht S; Hamman MA; Ambrosius WT; Bruce MA; Haehner-Daniels B; Hall SD
    Clin Pharmacol Ther; 2003 Sep; 74(3):275-87. PubMed ID: 12966371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytochrome p450 3A4 messenger ribonucleic acid induction by rifampin in human peripheral blood mononuclear cells: correlation with alprazolam pharmacokinetics.
    Gashaw I; Kirchheiner J; Goldammer M; Bauer S; Seidemann J; Zoller K; Mrozikiewicz PM; Roots I; Brockmöller J
    Clin Pharmacol Ther; 2003 Nov; 74(5):448-57. PubMed ID: 14586385
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rate of onset of inhibition of gut-wall and hepatic CYP3A by clarithromycin.
    Quinney SK; Malireddy SR; Vuppalanchi R; Hamman MA; Chalasani N; Gorski JC; Hall SD
    Eur J Clin Pharmacol; 2013 Mar; 69(3):439-48. PubMed ID: 22777148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole.
    Tsunoda SM; Velez RL; von Moltke LL; Greenblatt DJ
    Clin Pharmacol Ther; 1999 Nov; 66(5):461-71. PubMed ID: 10579473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping.
    Lee JI; Chaves-Gnecco D; Amico JA; Kroboth PD; Wilson JW; Frye RF
    Clin Pharmacol Ther; 2002 Dec; 72(6):718-28. PubMed ID: 12496753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oxidative metabolism of clarithromycin in the presence of human liver microsomes. Major role for the cytochrome P4503A (CYP3A) subfamily.
    Rodrigues AD; Roberts EM; Mulford DJ; Yao Y; Ouellet D
    Drug Metab Dispos; 1997 May; 25(5):623-30. PubMed ID: 9152603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genotype-phenotype associations of cytochrome P450 3A4 and 3A5 polymorphism with midazolam clearance in vivo.
    He P; Court MH; Greenblatt DJ; Von Moltke LL
    Clin Pharmacol Ther; 2005 May; 77(5):373-87. PubMed ID: 15900284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone.
    Kharasch ED; Hoffer C; Whittington D; Sheffels P
    Clin Pharmacol Ther; 2004 Sep; 76(3):250-69. PubMed ID: 15371986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CYP3A activity in African American and European American men: population differences and functional effect of the CYP3A4*1B5'-promoter region polymorphism.
    Wandel C; Witte JS; Hall JM; Stein CM; Wood AJ; Wilkinson GR
    Clin Pharmacol Ther; 2000 Jul; 68(1):82-91. PubMed ID: 10945319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7.
    Williams JA; Ring BJ; Cantrell VE; Jones DR; Eckstein J; Ruterbories K; Hamman MA; Hall SD; Wrighton SA
    Drug Metab Dispos; 2002 Aug; 30(8):883-91. PubMed ID: 12124305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes.
    Lalovic B; Phillips B; Risler LL; Howald W; Shen DD
    Drug Metab Dispos; 2004 Apr; 32(4):447-54. PubMed ID: 15039299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of the CYP3A5 genotype on the pharmacokinetics of intravenous midazolam during inhibited and induced metabolic states.
    Yu KS; Cho JY; Jang IJ; Hong KS; Chung JY; Kim JR; Lim HS; Oh DS; Yi SY; Liu KH; Shin JG; Shin SG
    Clin Pharmacol Ther; 2004 Aug; 76(2):104-12. PubMed ID: 15289787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women.
    Floyd MD; Gervasini G; Masica AL; Mayo G; George AL; Bhat K; Kim RB; Wilkinson GR
    Pharmacogenetics; 2003 Oct; 13(10):595-606. PubMed ID: 14515058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic contribution to variable human CYP3A-mediated metabolism.
    Lamba JK; Lin YS; Schuetz EG; Thummel KE
    Adv Drug Deliv Rev; 2002 Nov; 54(10):1271-94. PubMed ID: 12406645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of midazolam urinary metabolic ratios for cytochrome P450 3A (CYP3A) phenotyping.
    Streetman DS; Kashuba AD; Bertino JS; Kulawy R; Rocci ML; Nafziger AN
    Pharmacogenetics; 2001 Jun; 11(4):349-55. PubMed ID: 11434513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of the CYP oxidoreductase Ala503Val polymorphism on CYP3A activity in vivo: a randomized, open-label, crossover study in healthy Chinese men.
    Yang G; Fu Z; Chen X; Yuan H; Yang H; Huang Y; Ouyang D; Tan Z; Tan H; Huang Z; Zhou H
    Clin Ther; 2011 Dec; 33(12):2060-70. PubMed ID: 22177374
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.